← All trials
NCT03824535
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 4, 2019
- Primary completion
- Aug 1, 2022
- Completion date
- Aug 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Stanford UniversityLead sponsor
- Boston UniversityCollaborator
- Stanford UniversityOverall official - principal investigator
- Stanford UniversitySponsor investigator
- Canary FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.